This is a follow-up (containing more details) to an article I published earlier at: https://eogn.com/page-18080/13345504: 

Anne Wojcicki, the CEO of 23andMe, is considering a proposal to take the genetic testing company private after its stock price tumbled more than 95% from its 2021 highs. A late Wednesday filing with the Securities and Exchange Commission said Wojcicki is working with advisors and plans to speak with possible financing sources and partners. She “wishes to maintain control” of the company and will “not be willing to support any alternative transaction,” the filing said. […]

In November, 23andMe received a deficiency letter from the Nasdaq Listing Qualifications Department, which said the company had 180 days to bring its share price back above $1. The company’s board of directors formed a “Special Committee” in late March to help explore options that could juice the stock.